Panchenko E P, Komarov A L
Kardiologiia. 2012;52(9):44-52.
The review is devoted to pharmacogenetics of clopidogrel and its value for the clinic. Mechanism of action of clopidogrel and main trials which has proven its efficacy are presented as well as results of main large studies including authors own results demonstrating dependence of clinical efficacy of clopidogrel on carriage of polymorphisms of gene of CYP2C19 which accomplishes metabolism of the drug in the liver. Problems of interaction of clopidogrel with proton pump inhibitors and other drugs as well as ways of overcoming "resistance" to clopidogrel are considered. Clinical efficacy of other P2Y12 receptors of platelets in patients with IHD is characterized in comparison with clopidogrel.
本综述致力于氯吡格雷的药物遗传学及其临床价值。介绍了氯吡格雷的作用机制以及证实其疗效的主要试验,还介绍了主要大型研究的结果,包括作者自己的结果,这些结果表明氯吡格雷的临床疗效取决于肝脏中完成药物代谢的CYP2C19基因多态性的携带情况。考虑了氯吡格雷与质子泵抑制剂及其他药物的相互作用问题以及克服对氯吡格雷“抵抗”的方法。与氯吡格雷相比,对缺血性心脏病患者血小板其他P2Y12受体的临床疗效进行了描述。